BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...

Barrington analyst Michael Petusky lowered the firm’s price target on Haemonetics (HAE) to $95 from $108 and keeps an Outperform rating on the ...

Haemonetics Trading Up 3.4 % NYSE HAE opened at $71.26 on Thursday. Haemonetics has a one year low of $65.73 and a one year high of $97.97. The company has a debt-to-equity ratio of 1.39, a quick ...

Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per ...

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on ...

Haemonetics Corporation (NYSE:HAE) stock dropped about 12% after the blood supplies company missed Q3 revenue estimates, despite posting a 3.7% year-over-year increase. Quarterly revenue came in ...

Get Our Latest Stock Report on HAE Haemonetics Stock Performance Shares of Haemonetics stock opened at $66.15 on Monday. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt ...

BOSTON (AP) — BOSTON (AP) — Haemonetics Corp. (HAE) on Thursday reported fiscal third-quarter net income of $37.5 million. The Boston-based company said it had net income of 74 cents per share.

Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago. These figures are ...